Open an account

Celularity

CELU · NASDAQ

$1.26+$0.10 (+8.62%)TodayMarket closed ·
Prev close $1.16

About CELU

Celularity, Inc. is a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. The company is headquartered in Florham Park, New Jersey. The company went IPO on 2019-05-23. The firm is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. Its IMPACT manufacturing platform is a fully integrated process designed to optimize the speed of the sourcing of placentas from full-term healthy informed consent donors through the use of proprietary processing methods, cell selection, product-specific chemistry, manufacturing and control (CMC), advanced cell manufacturing and cryopreservation. The company also provides contract manufacturing and development services to third parties.

Employees
123
Headquarters
Florham Park, New Jersey
Listed
May 23, 2019
Sector
Health Care
Industry
Biotechnology
Website
celularity.com

CELU key statistics

Market cap
40.89M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
132.32K
Volume
60.15K
Open price
$1.16
High today
$1.30
Low today
$1.16
52 Week high
$2.55
52 Week low
$0.5601

Celularity (CELU) at a glance

Celularity (CELU) last traded at $1.26, with a market cap of 40.89M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.16 and $1.30. The current price is 8.6% above the day's low and 3.1% below its high.

Volume so far is 60.15K shares, below the average of 132.32K shares a day.

Over the past year Celularity has ranged from $0.5601 to $2.55, and now sits 35% of the way up that range.

Celularity met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q4 FY25 it reported -$0.85 per share against an estimate of -$1.53.

CELU earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 82.7% on average.

  1. Q4 FY22: reported $1.60 per share against an estimate of -$2.62
  2. Q1 FY23: reported -$4.10 per share against an estimate of -$2.45
  3. Q2 FY23: reported -$2.70 per share against an estimate of -$0.306
  4. Q3 FY23: reported -$5.00 per share against an estimate of -$0.306
  5. Q1 FY25: reported -$0.84 per share against an estimate of -$0.765
  6. Q2 FY25: reported -$1.02 per share against an estimate of -$0.765
  7. Q3 FY25: reported -$0.88 per share against an estimate of -$1.53
  8. Q4 FY25: reported -$0.85 per share against an estimate of -$1.53

CELU news

  • Rishabh Mishra

    Stock Market: Will S&P 500 Open Up or Down Today?

  • Rishabh Mishra

    Stock Market: Will S&P 500 Open Up or Down Today?

  • Vandana Singh

    Why Is Celularity Stock Gaining Thursday?

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Press releaseBusiness Wire

    Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® Platform

  • Avi Kapoor

    Dow Tumbles Over 1%; Nio Shares Edge Lower After Q2 Results

  • Avi Kapoor

    Nasdaq Down 1%; Signet Jewelers Earnings Top Views

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

Similar companies

Companies in the same industry as Celularity

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.